Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564233 | 0.77 | — | — | |
| SCHEMBL4051594 | 0.76 | RAB9A (0.38) | KDM4ELMNA | |
| SCHEMBL5464880 | 0.76 | — | — | |
| SCHEMBL4071162 | 0.73 | ALDH1A1 (0.41) | HIF1ACYP1A2MAPK1KDM4ELMNA | |
| SCHEMBL23120089 | 0.72 | BACE1 (0.42) | HIF1AGSTP1GSTM2CYP1A2MAPK1 | |
| SCHEMBL29594498 | 0.72 | BACE1 (0.42) | HIF1AGSTP1GSTM2CYP1A2MAPK1 | |
| SCHEMBL27095087 | 0.72 | CYP2D6 (0.32) | CYP1A2 | |
| SCHEMBL6482093 | 0.71 | MAOA (0.50) | HIF1AMAPK1 | |
| SCHEMBL6543393 | 0.71 | MAOA (0.50) | HIF1AMAPK1 | |
| SCHEMBL1496771 | 0.71 | MAOA (0.50) | HIF1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240060201-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-02-22 | — | — | US | disclosed |
| US-6248870-B1 | OLIGO-2,6-PYRIMIDINE COMPLEXING AGENT. | NYCOMED IMAGING AS (NO) | 2001-06-19 | — | — | US | disclosed |
| US-5817774-A | Unsymmetrical complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | STERLING WINTHROP INCORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5760191-A | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | NYCOMED IMAGING AS (NO) | 1998-06-02 | — | — | US | disclosed |
| US-5559214-A | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods | STERLING WINTHROP INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240060201-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | SLC39A11, SCN11A, S100A11 | HIF1A 4288/4885GSTP1 2395/4885GSTM2 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.